ACRV · Insider Trading
Acrivon Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by ACRV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-26 | Mary Miller | Chief Legal Officer | Sell | −513 | −$944 |
| 2026-10-07 | Mary Miller | Chief Legal Officer | Sell | −294 | −$585 |
| 2026-09-02 | Michaela Levin | Chief Business Officer | A | +30,000 | — |
| 2026-08-27 | Kristina Masson | EVP - Business Operations | Sell | −28,072 | −$61.94K |
| 2026-08-20 | Eric Devroe | Chief Operating Officer | Sell | −604 | −$1.21K |
| 2026-08-20 | Katharine Peterson | Chief Accounting Officer | Sell | −101 | −$203 |
| 2026-08-20 | Mary Miller | Chief Legal Officer | Sell | −185 | −$372 |
| 2026-08-20 | Kristina Masson | EVP - Business Operations | Sell | −3,426 | −$6.89K |
| 2026-08-20 | Erick Gamelin | Chief Development Officer | Sell | −400 | −$804 |
| 2026-08-06 | Adam D. Levy | Chief Financial Officer | Sell | −1,142 | −$1.79K |
| 2026-08-06 | Adam D. Levy | Chief Financial Officer | Sell | −1,142 | −$1.79K |
| 2026-07-23 | Mary Miller | Chief Legal Officer | Sell | −573 | −$1.01K |
| 2026-06-22 | Charles M Baum | Director | A | +20,275 deriv. | — |
| 2026-06-22 | Sharon Shacham | Director | A | +20,275 deriv. | — |
| 2026-06-22 | Derek DiRocco | Director | A | +20,275 deriv. | — |
| 2026-06-22 | Santhosh Palani | Director | A | +20,275 deriv. | — |
| 2026-06-22 | Michael John Tomsicek | Director | A | +20,275 deriv. | — |
| 2026-06-22 | Rajeev M. Shah | Director | A | +101,375 deriv. | — |
| 2026-06-22 | Ivana Magovcevic-Liebisch | Director | A | +20,275 deriv. | — |
| 2026-05-26 | Peter Blume-Jensen | President and CEO | F | −27,458 | −$49.15K |
| 2026-05-20 | Katharine Peterson | Chief Accounting Officer | A | +14,227 | — |
| 2026-05-20 | Eric Devroe | Chief Operating Officer | A | +72,981 | — |
| 2026-05-20 | Mary Miller | Chief Legal Officer | A | +49,830 | — |
| 2026-05-20 | Charles M Baum | Director | A | +9,366 | — |
| 2026-05-20 | Ivana Magovcevic-Liebisch | Director | A | +9,366 | — |
| 2026-05-20 | Sharon Shacham | Director | A | +9,366 | — |
| 2026-05-20 | Adam D. Levy | Chief Financial Officer | A | +46,167 | — |
| 2026-05-20 | Santhosh Palani | Director | A | +9,366 | — |
| 2026-05-20 | Derek DiRocco | Director | A | +9,366 | — |
| 2026-05-20 | Kristina Masson | EVP - Business Operations | A | +505,602 | — |
| 2026-05-20 | Michael John Tomsicek | Director | A | +9,366 | — |
| 2026-05-20 | Mansoor Raza Mirza | Chief Medical Officer | A | +38,817 | — |
| 2026-05-20 | Rajeev M. Shah | Director | A | +46,830 | — |
| 2026-05-20 | Erick Gamelin | Chief Development Officer | A | +38,584 | — |
| 2026-05-18 | Erick Gamelin | Chief Development Officer | F | −404 | −$776 |
| 2026-05-18 | Katharine Peterson | Chief Accounting Officer | F | −99 | −$190 |
| 2026-05-18 | Mary Miller | Chief Legal Officer | F | −184 | −$353 |
| 2026-05-18 | Eric Devroe | Chief Operating Officer | F | −613 | −$1.18K |
| 2026-05-18 | Kristina Masson | EVP - Business Operations | F | −3,486 | −$6.69K |
| 2026-04-23 | RA Capital Healthcare Fund LP | Director | A | +19,444,440 | +$35.00M |
| 2026-04-21 | Mary Miller | Chief Legal Officer | F | −558 | −$993 |
| 2026-03-03 | Mary Miller | Chief Legal Officer | A | +129,760 deriv. | — |
| 2026-03-03 | Katharine Peterson | Chief Accounting Officer | A | +31,900 deriv. | — |
| 2026-03-03 | Eric Devroe | Chief Operating Officer | A | +186,728 deriv. | — |
| 2026-03-03 | Peter Blume-Jensen | President and CEO | A | +1,205,410 deriv. | — |
| 2026-03-03 | Erick Gamelin | Chief Development Officer | A | +94,946 deriv. | — |
| 2026-03-03 | Mansoor Raza Mirza | Chief Medical Officer | A | +174,068 deriv. | — |
| 2026-03-03 | Adam D. Levy | Chief Financial Officer | A | +132,925 deriv. | — |
| 2026-02-24 | Peter Blume-Jensen | President and CEO | F | −28,530 | −$43.65K |
| 2026-02-18 | Eric Devroe | Chief Operating Officer | F | −723 | −$1.18K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Joseph Edelman | 10%+ Owner | 3,104,139 | $5.34M |
| Peter Blume-Jensen | President and CEO | 2,631,660 | $4.53M |
| Kristina Masson | EVP - Business Operations | 2,615,911 | $4.50M |
| RA Capital Healthcare Fund LP | Director | 426,302 | $733.24K |
| Eric Devroe | Chief Operating Officer | 146,349 | $251.72K |
| Mary Miller | Chief Legal Officer | 81,715 | $140.55K |
| Adam D. Levy | Chief Financial Officer | 66,008 | $113.53K |
| Erick Gamelin | Chief Development Officer | 52,592 | $90.46K |
| Mansoor Raza Mirza | Chief Medical Officer | 38,817 | $66.77K |
| Michaela Levin | Chief Business Officer | 30,000 | $51.60K |
| Rasmus Holm-Jorgensen | Chief Financial Officer | 26,088 | $44.87K |
| Katharine Peterson | Chief Accounting Officer | 18,033 | $31.02K |
| Derek DiRocco | Director | 9,366 | $16.11K |
| Rajeev M. Shah | Director | 9,366 | $16.11K |
| Sharon Shacham | Director | 9,366 | $16.11K |
| Charles M Baum | Director | 9,366 | $16.11K |
| Santhosh Palani | Director | 9,366 | $16.11K |
| Michael John Tomsicek | Director | 9,366 | $16.11K |
| Ivana Magovcevic-Liebisch | Director | 9,366 | $16.11K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ACRV quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.